Cancidas Related Published Studies
Well-designed clinical trials related to Cancidas (Caspofungin)
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). [2011.09]
Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. [2011.07]
Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. [2011.02]
Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin. [2011.01]
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. [2010.05]
A randomized, double-blind, multicenter study of caspofungin versus liposomal
amphotericin B for empiric antifungal therapy in pediatric patients with
persistent fever and neutropenia. [2010]
An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. [2009.07]
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. [2009.06.15]
Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. [2009.06]
An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. [2009.01.12]
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. [2007.10.01]
Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. [2006.03]
Potential for interactions between caspofungin and nelfinavir or rifampin. [2004.11]
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. [2004.09.30]
Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. [2003.08]
Comparison of caspofungin and amphotericin B for invasive candidiasis. [2002.12.19]
Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. [2002.09.01]
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. [2002.09]
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. [2002.03]
Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. [2002.02]
A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. [2001.11.01]
Well-designed clinical trials possibly related to Cancidas (Caspofungin)
Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. [2011.05]
Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. [2011.02]
Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. [2010.02]
Efungumab: a novel agent in the treatment of invasive candidiasis. [2009.11]
Efungumab: A Novel Agent in the Treatment of Invasive Candidiasis (November). [2009.09.22]
Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. [2009]
Double-blind active-control trials: beware the comparator you keep. [2008.10.15]
Invasive candidiasis in cancer patients: observations from a randomized clinical trial. [2005.06]
Other research related to Cancidas (Caspofungin)
A double-blind comparative study of the safety and efficacy of caspofungin versus
micafungin in the treatment of candidiasis and aspergillosis. [2013]
Caspofungin for prophylaxis and treatment of fungal infections in adolescents and
adults: a meta-analysis of randomized controlled trials. [2012]
Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical
antifungal therapy of febrile neutropenia in Australia. [2012]
Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients. [2011.11.14]
Determination of the therapeutic activity of caspofungin compared with the amphotericin B in an animal experimental model of histoplasmosis in hamster (Mesocrisetus auratus). [2011.10]
Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. [2011.07.26]
Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. [2011.07]
Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. [2011.07]
Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. [2011.07]
Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. [2011.06]
Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. [2011.06]
Candidemia in children after complex congenital heart defects surgery treated with caspofungin--our own experience and a review of literature. [2011.05]
Treatment of Alternaria keratitis with intrastromal and topical caspofungin in combination with intrastromal, topical, and oral voriconazole. [2011.05]
Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. [2011.05]
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. [2011.04.28]
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature. [2011.04.28]
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. [2011.04.28]
Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature. [2011.04.28]
Caspofungin therapy in immunocompromised children and neonates. [2011.03]
A Randomized, Double-Blind, Prospective Study of Caspofungin vs. Amphotericin B for the Treatment of Invasive Candidiasis in Newborn Infants. [2011.02.25]
Conservative management of Candida infection of prosthetic aortic graft by means of caspofungin and fluconazole alone. [2011]
Economic evaluation of caspofungin versus liposomal amphotericin B for empirical
antifungal therapy in patients with persistent fever and neutropenia in Sweden. [2011]
Lack of pharmacokinetic drug interaction between oral posaconazole and
caspofungin or micafungin. [2011]
Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. [2010.10]
A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver function tests while on caspofungin. [2010.07.21]
Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. [2010.07]
Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry. [2010.06.22]
Lack of Pharmacokinetic Drug Interaction Between Oral Posaconazole and Caspofungin or Micafungin. [2010.05.20]
Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. [2010.05]
[Specific antifungal treatment in patients with neutropenia and fever: current status of the fungicidal activity of caspofungin] [2010.04]
In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin. [2010.04]
Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. [2010.04]
Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. [2010.04]
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. [2010.03]
Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. [2010.02]
Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. [2010.02]
An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. [2009.12]
Safety experience with caspofungin in pediatric patients. [2009.12]
Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. [2009.11]
Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. [2009.09]
Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium. [2009.09]
Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. [2009.08]
Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. [2009.07]
Breakthrough rhinocerebral mucormycosis in a liver transplant patient receiving caspofungin. [2009.06]
Neonatal liver abscesses due to Candida infection effectively treated with caspofungin. [2009.05]
Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. [2009.05]
Pharmacokinetics and safety of caspofungin in older infants and toddlers. [2009.04]
A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. [2009.03]
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. [2009.03]
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. [2009.03]
Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. [2009.02.15]
Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. [2009.01.27]
Combined therapy with amphotericin B and caspofungin in an experimental model of disseminated histoplasmosis. [2009.01]
Alternaria keratitis: clinical presentation and resolution with topical fluconazole or intrastromal voriconazole and topical caspofungin. [2009.01]
Caspofungin: in pediatric patients with fungal infections. [2009]
Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. [2008.11]
Caspofungin. [2008.11]
[Tolerance of caspofungin in intensive care unit: a prospective study] [2008.10]
Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. [2008.10]
Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital. [2008.09]
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. [2008.08.01]
Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections. [2008.08]
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. [2008.08]
Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. [2008.07.15]
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. [2008.07]
Combination Polyene-Caspofungin Treatment of Rhino-Orbital-Cerebral Mucormycosis. [2008.06.17]
Caspofungin disk diffusion breakpoints and quality control. [2008.06]
Economic Evaluation of Caspofungin versus Liposomal Amphotericin B for Empiric Antifungal Treatment in Patients with Neutropenic Fever in Italy. [2008.05.20]
Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin. [2008.05.15]
Successful treatment of disseminated Geotrichum capitatum infection with a combination of caspofungin and voriconazole in an immunocompromised patient. [2008.05]
Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. [2008.05]
Comparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasis. [2008.05]
|
